Management of menopausal disorders in women at risk: potential and advantages of transdermal estrogen

Literature review

Authors

DOI:

https://doi.org/10.18370/2309-4117.2024.74.39-46

Keywords:

perimenopause, menopause, menopausal hormone therapy, risk groups, transdermal estrogens, micronized progesterone

Abstract

Background. Global trends of increasing life expectancy against the background of a decrease in the average age of natural menopause highlight the problem of qualified management of this contingent of women. The menopausal period can be associated with many clinical signs, such as vasomotor symptoms, genitourinary problems and additional psychological disorders (anxiety, mood swings and sleep disorders). Ignoring the first symptoms of age-related changes can lead to a decrease in the quality of life, workforce productivity and general health deterioration.
Objective of the review: to analyze modern approaches to the management of patients with menopausal disorders in risk groups; to study the possibilities and benefits of transdermal estrogen.
Analysis of literary data. The key link in the pathogenesis of menopausal disorders is objectively considered to be a decrease in estrogen synthesis in the ovaries, which leads to the development of clinical symptoms of menopause and a significant increase in the risk of developing cardiovascular diseases, obesity, diabetes, bone loss, osteoporosis, etc.
Timely administration of menopausal hormone therapy is currently considered the most effective method of treating vasomotor symptoms, genitourinary syndrome, sleep disorders and emotional changes in women. The management of this women contingent requires the mandatory consideration of absolute and relative contraindications to the appointment of hormonal therapy. The general management strategy of women with menopausal disorders, including genitourinary menopausal syndrome, involves a comprehensive approach to diagnosis and treatment. Its important component is the use of menopausal hormone therapy, taking into account contraindications in women at risk of developing cardiovascular, thrombotic, and metabolic complications.
Educating health care professionals about the benefits of hormone therapy, including transdermal estrogens potential, will optimize menopausal management and reduce the various risks and adverse effects of oral administration. In this context, the use of the transdermal form of 17β-estradiol (Estrogel) and the original micronized progesterone medication (Utrozhestan) in menopausal disorder management regimens, given their proven efficacy, is gaining clinical significance for the correction of estrogen deficiency and its symptoms, particularly in risk groups. 
Conclusions. Management of patients with menopausal disorders is a matter of a personalized approach to choosing the optimal treatment regimen with adherence to the principles: timely, effective and as safe as possible.

Author Biographies

V.H. Sіusіuka, Zaporizhzhia State Medical and Pharmaceutical University, Zaporizhzhia

MD, professor, head of the Department of Obstetrics and Gynecology

M.Y. Sergienko, Zaporizhzhia State Medical and Pharmaceutical University, Zaporizhzhia

PhD, associate professor, Department of Obstetrics and Gynecology

M.I. Pavliuchenko, Zaporizhzhia State Medical and Pharmaceutical University, Zaporizhzhia

PhD, associate professor, Department of Obstetrics and Gynecology

O.V. Demidenko, Zaporizhzhia State Medical and Pharmaceutical University, Zaporizhzhia

PhD, associate professor, head of the Department of Internal Medicine No. 2

O.V. Deinichenko, Zaporizhzhia State Medical and Pharmaceutical University, Zaporizhzhia

PhD, associate professor, Department of Obstetrics and Gynecology

S.Р. Onopchenko, Zaporizhzhia State Medical and Pharmaceutical University, Zaporizhzhia

PhD, assistant, Department of Obstetrics and Gynecology

References

  1. Unified clinical protocol of primary, secondary (specialized), tertiary (highly specialized) medical care «Menopausal disorders and other disorders in the perimenopausal period». Order dated 2022 Jun 17, No. 1039. [Internet]. Ministry of Health of Ukraine. 2022 [cited 2024 Apr 1]. Ukrainian. Available from: https://www.dec.gov.ua/wp-content/uploads/2022/06/37474-dn_1039_17_06_2022_dod.pdf
  2. Evidence-based clinical guidelines «Menopausal disorders and other disorders in the perimenopausal period» [Internet]. Ministry of Health of Ukraine. 2022 [cited 2024 Apr 1]. Ukrainian. Available from: https://www.dec.gov.ua/wp-content/uploads/2022/06/2022_01_13_kn_menopauz_ rozlady.pdf
  3. Paciuc J. Hormone Therapy in Menopause. Adv Exp Med Biol. 2020;1242:89–120. DOI: 10.1007/978-3-030-38474-6_6
  4. Peacock K, Carlson K, Ketvertis KM. Menopause. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan. Available from: https://www.ncbi.nlm. nih.gov/books/NBK507826/
  5. Zhang GQ, Chen JL, Luo Y, et al. Menopausal hormone therapy and women’s health: An umbrella review. PLoS Med. 2021;2,18(8):e1003731. DOI: 10.1371/journal.pmed.1003731
  6. Cesari M, Sumi Y, Han ZA, et al. Implementing care for healthy ageing. BMJ Glob Health. 2022;7(2):e007778. DOI: 10.1136/bmjgh-2021-007778
  7. Zahorodnia O, Voshkulat Y, Kupchik L. The influence of menopausal hormone therapy on somatic morbidity in postmenopausal women. Reproductive Health of Woman. 2024:3;60–7. DOI: 10.30841/2708-8731.3.2024.304918
  8. Santoro N, Roeca C, Peters BA, Neal-Perry G.The Menopause Transition: Signs, Symptoms, and Management Options. J Clin Endocrinol Metab. 2021;106(1):1–15. DOI:10.1210/clinem/dgaa764
  9. Dothard MI, Allard SM, Gilbert JA. The effects of hormone replacement therapy on the microbiomes of postmenopausal women. Climacteric. 2023;26(3):182–92. DOI:10.1080/13697137.2023.2173568
  10. Aquino CI, Stampini V, Osella E, et al. Menopausal Hormone Therapy, an Ever-Present Topic: A Pilot Survey about Women’s Experience and Medical Doctors’ Approach. Medicina (Kaunas). 2024;60(5):774. DOI:10.3390/medicina60050774
  11. Jeong HG, Park H. Metabolic Disorders in Menopause. Metabol. 2022;8,12(10):954. DOI: 10.3390/metabo12100954
  12. Resolution of The II International Menopause Expert Forum. Reprod Endocrinol. 2021;(60):77–84. DOI: 10.18370/2309- 4117.2021.60.77-84
  13. Gu Y, Han F, Xue M, Wang M, Huang Y. The benefits and risks of menopause hormone therapy for the cardiovascular system in postmenopausal women: a systematic review and meta-analysis. BMC Womens Health. 2024;24(1):60. DOI:10.1186/s12905-023-02788-0
  14. Paschou SA, Athanasiadou KI, Papanas N. Menopausal Hormone Therapy in Women with Type 2 Diabetes Mellitus: An Updated Review. Diabetes Ther. 2024;15(4):741–8. DOI:10.1007/s13300-024-01546-1
  15. Agababyan L, Begimbekova L, Vasylchenko L, et al. V International expert forum on menopausal hormone therapy. Reproductive endocrinology. 2024;71:10–8. DOI: 10.18370/2309-4117.2024.71.10-18
  16. Genazzani AR, Monteleone P, Giannini A, Simoncini T. Hormone therapy in the postmenopausal years: considering benefits and risks in clinical practice. Hum Reprod Update. 2021;27(6):1115–50. DOI:10.1093/humupd/dmab026
  17. Lambrinoudaki I, Armeni E, Goulis D, et al. Menopause, wellbeing and health: A care pathway from the European Menopause and Andropause Society. Maturitas. 2022;163:1–14. DOI:10.1016/j.maturitas.2022.04.008
  18. Instructions for medical use of the drug Oestrogel [Internet]. Available from: https://mozdocs.kiev.ua/likiview.php?id=49126
  19. Instructions for medical use of the drug Utrogestan [Internet]. Available from: https://mozdocs.kiev.ua/likiview.php?id=47683
  20. L’Hermite M. HRT optimization, using transdermal estradiol plus micronized progesterone, a safer HRT. Climacteric. 2013;16,1:44–53. DOI:10.3109/13697137.2013.808563
  21. Lizcano F. Roles of estrogens, estrogen-like compounds, and endocrine disruptors in adipocytes. Front Endocrinol (Lausanne). 2022;13:921504. DOI:10.3389/fendo.2022.921504
  22. Newman MS, Saltiel D, Smeaton J, Stanczyk FZ. Comparative estrogen exposure from compounded transdermal estradiol creams and Food and Drug Administration-approved transdermal estradiol gels and patches. Menopause. 2023;30(11):1098–105. DOI:10.1097/GME.0000000000002266
  23. Crandall CJ, Mehta JM, Manson JE. Management of Menopausal Symptoms: A Review. JAMA. 2023;329(5):405–20. DOI:10.1001/jama.2022.24140
  24. Liu Q, Huang Z, Xu P. Effects of hormone replacement therapy on mood and sleep quality in menopausal women. World J Psychiatry. 2024;14(7):1087–94. DOI:10.5498/wjp.v14.i7.1087
  25. Barcellona D, Grandone E, Marongiu F. Hormones and thrombosis: the dark side of the moon. Blood Transfus. 2024;22(1):46–54. DOI:10.2450/BloodTransfus.535
  26. Boardman HM, Hartley L, Eisinga A, et al. Hormone therapy for preventing cardiovascular disease in post-menopausal women. Cochrane Database Syst Rev. 2015;2015(3):CD002229. DOI:10.1002/14651858.CD002229.pub4
  27. Kapoor E, Kling JM, Lobo AS, Faubion SS. Menopausal hormone therapy in women with medical conditions. Best Pract Res Clin Endocrinol Metab. 2021;35(6):101578. DOI:10.1016/j.beem.2021.101578
  28. «The 2022 Hormone Therapy Position Statement of The North American Menopause Society» Advisory Panel. The 2022 hormone therapy position statement of The North American Menopause Society. Menopause. 2022;29(7):767–94. DOI:10.1097/GME.0000000000002028
  29. Eubanks A. Hormone Therapy: Menopausal Hormone Therapy. FP Essent. 2023;531:15–21.
  30. «The 2023 Nonhormone Therapy Position Statement of The North American Menopause Society» Advisory Panel. The 2023 nonhormone therapy position statement of The North American Menopause Society. Menopause. 2023 Jun 1;30(6):573–90. DOI: 10.1097/GME.0000000000002200
  31. Anagnostis P, Stevenson JC. Cardiovascular health and the menopause, metabolic health. Best Pract Res Clin Endocrinol Metab. 2024;38(1):101781. DOI:10.1016/j.beem.2023.101781
  32. Tatarchuk T, Zakharenko N, Reheda S, Kvasha T. Algorithms for prescribing menopausal hormone therapy in different periods of menopause. Reproductive endocrinology. (2022);4(66):68–70. DOI: 10.18370/2309-4117.2022.66.68-70
  33. Plu-Bureau G, Mounier-Vehier C. Traitement hormonal de ménopause et risque cardiovasculaire. RPC Les femmes ménopausées du CNGOF et du GEMVi [Menopausal hormone therapy an cardiovascular risk. Postmenopausal women management: CNGOF and GEMVi clinical practice guidelines]. Gynecol Obstet Fertil Senol. 2021;49(5):438–47. DOI:10.1016/j.gofs.2021.03.017
  34. Trémollieres FA, Chabbert-Buffet N, Plu-Bureau G, et al. Management of postmenopausal women: Collège National des Gynécologues et Obstétriciens Français (CNGOF) and Groupe d’Etude sur la Ménopause et le Vieillissement (GEMVi) Clinical Practice Guidelines. Maturitas. 2022;163:62–81. DOI:10.1016/j.maturitas.2022.05.008
  35. Shufelt CL, Manson JE. Menopausal Hormone Therapy and Cardiovascular Disease: The Role of Formulation, Dose, and Route of Delivery. J Clin Endocrinol Metab. 2021;23,106(5):1245–54. DOI: 10.1210/clinem/dgab042
  36. Files J, Kling JM. Transdermal delivery of bioidentical estrogen in menopausal hormone therapy: a clinical review. Expert Opin Drug Deliv. 2020;17(4):543–9. DOI:10.1080/17425247.2020.1700949
  37. Harper-Harrison G, Carlson K, Shanahan MM. Hormone Replacement Therapy. In: StatPearls. Treasure Island (FL): StatPearls Publishing; October 6, 2024.
  38. Laliberté F, Dea K, Duh MS, et al. Does the route of administration for estrogen hormone therapy impact the risk of venous thromboembolism? Estradiol transdermal system versus oral estrogen-only hormone therapy. Menopause. 2018;25(11):1297–305. DOI:10.1097/GME.0000000000001232
  39. Hugon-Rodin J, Perol S, Plu-Bureau G. Ménopause et risque thromboembolique veineux. RPC Les femmes ménopausées du CNGOF et du GEMVi [Menopause and risk of thromboembolic events. Postmenopausal women management: CNGOF and GEMVi clinical practice guidelines]. Gynecol Obstet Fertil Senol. 2021;49(5):455–61. DOI:10.1016/j.gofs.2021.03.018
  40. Sobel TH, Shen W. Transdermal estrogen therapy in menopausal women at increased risk for thrombotic events: a scoping review. Menopause. 2022;29(4):483–90. DOI:10.1097/GME.0000000000001938
  41. Morris G, Talaulikar V. Hormone replacement therapy in women with history of thrombosis or a thrombophilia. Post Reprod Health. 2023;29(1):33–41. DOI:10.1177/20533691221148036
  42. Anagnostis P, Lambrinoudaki I, Stevenson JC, Goulis DG. Menopause-associated risk of cardiovascular disease. Endocr Connect. 2022;11(4):e210537. DOI:10.1530/EC-21-0537
  43. Paschou SA, Papanas N. Type 2 Diabetes Mellitus and Menopausal Hormone Therapy: An Update. Diabetes Ther. 2019;10(6):2313–20. DOI:10.1007/s13300-019-00695-y
  44. L’Hermite M. Bioidentical menopausal hormone therapy: registered hormones (non-oral estradiol ± progesterone) are optimal. Climacteric. 2017;20(4):331–8. DOI:10.1080/13697137.2017.1291607
  45. Sumino H, Ichikawa S, Kasama S, et al. Different effects of oral conjugated estrogen and transdermal estradiol on arterial stiffness and vascular inflammatory markers in postmenopausal women. Atherosclerosis. 2006;189(2):436–42. DOI:10.1016/j.atherosclerosis.2005.12.030
  46. Mills KT, Stefanescu A, He J. The global epidemiology of hypertension. Nat Rev Nephrol. 2020;16(4):223–37. DOI:10.1038/s41581-019-0244-2
  47. Palacios S, Chedraui P, Sánchez-Borrego R, et al. Obesity and menopause. Gynecol Endocrinol. 2024;40(1):2312885. DOI:10.1080/09513590.2024.2312885
  48. Opoku AA, Abushama M, Konje JC. Obesity and menopause. Best Pract Res Clin Obstet Gynaecol. 2023;88:102348. DOI:10.1016/j.bpobgyn.2023.102348
  49. O’Sullivan AJ, Crampton LJ, Freund J, Ho KK. The route of estrogen replacement therapy confers divergent effects on substrate oxidation and body composition in postmenopausal women. J Clin Invest. 1998;102(5):1035–40. DOI:10.1172/JCI2773
  50. Ho KK, O’Sullivan AJ, Wolthers T, Leung KC. Metabolic effects of oestrogens: impact of the route of administration. Ann Endocrinol (Paris). 2003;64(2):170–7.
  51. dos Reis CM, de Melo NR, Meirelles ES, et al. Body composition, visceral fat distribution and fat oxidation in postmenopausal women using oral or transdermal oestrogen. Maturitas. 2003;46(1):59–68. DOI:10.1016/s0378-5122(03)00159-2
  52. Dam TV, Dalgaard LB, Ringgaard S, et al. Transdermal Estrogen Therapy Improves Gains in Skeletal Muscle Mass After 12 Weeks of Resistance Training in Early Postmenopausal Women. Front Physiol. 2021;11:596130. DOI:10.3389/fphys.2020.596130
  53. Dam TV, Dalgaard LB, Johansen FT, et al. Effects of transdermal estrogen therapy on satellite cell number and molecular markers for muscle hypertrophy in response to resistance training in early postmenopausal women. Eur J Appl Physiol. 2023;123(3):667–81. DOI:10.1007/s00421-022-05093-0
  54. Paschou SA, Anagnostis P, Pavlou DI,et al. Diabetes in Menopause: Risks and Management. Curr Vasc Pharmacol. 2019;17(6):556–63. DOI:10.2174/1570161116666180625124405
  55. Paschou SA, Marina LV, Spartalis E, et al. Therapeutic strategies for type 2 diabetes mellitus in women after menopause. Maturitas. 2019;126:69–72. DOI:10.1016/j.maturitas.2019.05.003
  56. Gray KE, Katon JG, LeBlanc ES, et al. Vasomotor symptom characteristics: are they risk factors for incident diabetes? Menopause. 2018;25(5):520–30. DOI: 10.1097/GME.0000000000001033
  57. Slopien R, Wender-Ozegowska E, Rogowicz-Frontczak A, et al. Menopause and diabetes: EMAS clinical guide. Maturitas. 2018;117:6–10. DOI: 10.1016/j.maturitas.2018.08.009
  58. Nappi RE, Simoncini T. Menopause transition: a golden age to prevent cardiovascular disease. Lancet Diabetes Endocrinol. 2021;9(3):135–7. DOI: 10.1016/S2213-8587(21)00018-8
  59. Bilodid OO. Safety of menopauseal hormonal therapy when using transdermal routes of hormone administration. Women’s doctor. 2024;3(113):28–35.
  60. Borozan S, Kamrul-Hasan ABM, Pappachan JM. Hormone replacement therapy for menopausal mood swings and sleep quality: The current evidence. World J Psychiatry. 2024;14(10):1605–10. DOI:10.5498/wjp.v14.i10.1605
  61. Gordon JL, Rubinow DR, Eisenlohr-Moul TA, et al. Efficacy of Transdermal Estradiol and Micronized Progesterone in the Prevention of Depressive Symptoms in the Menopause Transition: A Randomized Clinical Trial. JAMA Psychiatry. 2018;75(2):149–57. DOI:10.1001/jamapsychiatry.2017.3998
  62. David PS, Sobel T, Sahni S, et al. Menopausal Hormone Therapy in Older Women: Examining the Current Balance of Evidence. Drugs Aging. 2023;40(8):675-683. DOI:10.1007/s40266-023-01043-3
  63. Lorite MI, Cuadros AM, Rivera-Izquierdo M, et al. Benefits for cardiovascular system, bone density, and quality of life of a long-term hormone therapy in hysterectomized women: a 20-year follow-up study. Menopause. 2023;1,30(10):995–1001. DOI: 10.1097/GME.0000000000002239
  64. Oliver-Williams C, Glisic M, Shahzad S, Brown E, et al. The route of administration, timing, duration and dose of postmenopausal hormone therapy and cardiovascular outcomes in women: a systematic review. Hum Reprod Update. 2019;1,25(2):257–71. DOI: 10.1093/humupd/dmy039.

Downloads

Published

2024-11-29

How to Cite

Sіusіuka V., Sergienko, M., Pavliuchenko, M., Demidenko, O., Deinichenko, O., & Onopchenko, S. (2024). Management of menopausal disorders in women at risk: potential and advantages of transdermal estrogen: Literature review. REPRODUCTIVE ENDOCRINOLOGY, (74), 39–46. https://doi.org/10.18370/2309-4117.2024.74.39-46

Issue

No. 74 (2024)

Section

Management of menopause

License

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors who publish with this journal agree to the following terms:

    1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.

    1. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.